The type I interferon system in the etiopathogenesis of auto(10)

82.SanterDM,YoshioT,MinotaS,MollerT,ElkonKB.Potent

inductionofIFN-aandchemokinesbyautoantibodiesinthecerebrospinal uidofpatientswithneuropsychiatriclupus.JImmunol.2009;182:1192–201.

83.FairhurstAM,MathianA,ConnollyJE,WangA,GrayHF,

GeorgeTA,etal.SystemicIFN-adriveskidneynephritisinB6.Sle123mice.EurJImmunol.2008;38:1948–60.

84.PetersonKS,HuangJF,ZhuJ,D’AgatiV,LiuX,

MillerN,etal.Characterizationofheterogeneityinthemolecularpathogenesisoflupusnephritisfromtranscriptionalpro lesoflaser-capturedglomeruli.JClinInvest.2004;113:1722–33.

85.KaplanMJ,SalmonJE.HowdoesIFN-alphainsultthe

vasculature?letmecounttheways.ArthritisRheum.2011;63:334–6.

86.DennyMF,ThackerS,MehtaH,SomersEC,DodickT,

BarratFJ,etal.Interferon-apromotesabnormalvasculogen-esisinlupus:apotentialpathwayforprematureatheroscle-rosis.Blood.2007;110:2907–15.

87.LoodC,AmistenS,GullstrandB,JonsenA,AllhornM,

TruedssonL,etal.Platelettranscriptionalpro leandproteinexpressioninpatientswithsystemiclupuserythema-tosus:up-regulationofthetypeIinterferonsystemisstronglyassociatedwithvasculardisease.Blood.2010;116:1951–7.

88.LiJ,FuQ,CuiH,QuB,PanW,ShenN,etal.Interferon-a

primingpromoteslipiduptakeandmacrophage-derivedfoamcellformation:anovellinkbetweeninterferon-a.

y

landatherosclerosisinlupus.ArthritisRheum.2011;63:no 492–502.

esu89.NiessnerA,ShinMS,PryshchepO,GoronzyJJ,ChaikofEL,

l anWeyandCM.Synergisticproin ammatoryeffectsoftheosantiviralcytokineinterferon-aandToll-likereceptorrep4ligandsintheatheroscleroticplaque.Circulation.2007; rFo116:2043–52.

90.GatevaV,SandlingJK,HomG,TaylorKE,ChungSA,

SunX,etal.Alarge-scalereplicationstudyidenti esTNIP1,PRDM1,JAZF1,UHRF1BP1andIL10asrisklociforsystemiclupuserythematosus.NatGenet.2009;41:1228–33.

ThetypeIinterferoninautoimmunediseases

237

91.RönnblomL,AlmGV,ElorantaML.ThetypeIinterferon

systeminthedevelopmentoflupus.SeminImmunol.2011;23:113–21.

92.Santiago-RaberML,BaccalaR,HaraldssonKM,

ChoubeyD,StewartTA,KonoDH,etal.Type-Iinterferonreceptorde ciencyreduceslupus-likediseaseinNZBmice.JExpMed.2003;197:777–88.

93.BraunD,GeraldesP,DemengeotJ.TypeIinterferoncontrols

theonsetandseverityofautoimmunemanifestationsinlprmice.JAutoimmun.2003;20:15–25.

94.WallaceDJ,PetriM,OlsenN,KirouK,DennisG,

YaoY,etal.MEDI-545,ananti-interferonalphamonoclonalantibody,showsevidenceofclinicalactivityinsystemiclupuserythematosus.ArthritisRheum.2007;56:S562–3.

95.McBrideJM,WallaceDJ,YaoZ,MorimotoA,JiangJ,

MaciucaR,etal.Dose-dependentmodulationofinterferonregulatedgeneswithadministrationofsingleandrepeatdosesofrontalizumabinaphaseI,placebocontrolled,doubleblind,doseescalationstudyinSLE.ACRAnnualScienti cMeeting2009.

96.YaoY,RichmanL,HiggsBW,MorehouseCA,

delosReyesM,BrohawnP,etal.Neutralizationofinter-feron-a?b-induciblegenesanddownstreameffectinaphaseItrialofananti-interferon-amonoclonalantibodyinsystemiclupuserythematosus.ArthritisRheum.2009;60:1785–96.97.RönnblomL,AlmGV.AnetiopathogenicroleforthetypeI

IFNsysteminSLE.TrendsImmunol.2001;22:427–31.98.PestkaS,KrauseCD,WalterMR.Interferons,interferon-like

cytokines,andtheirreceptors.ImmunolRev.2004;202:8–32.99.DzionekA,SohmaY,NagafuneJ,CellaM,ColonnaM,

FacchettiF,etal.BDCA-2,anovelplasmacytoiddendriticcell-speci ctypeIIC-typelectin,mediatesantigencaptureandisapotentinhibitorofinterferona?binduction.JExpMed.2001;194:1823–34.

100.BarratFJ,CoffmanRL.DevelopmentofTLRinhibitorsfor

thetreatmentofautoimmunediseases.ImmunolRev.2008;223:271–83.

101.RönnblomL.PotentialroleofIFNainadultlupus.Arthritis

ResTher.2010;121S3.

Ups J Med Sci Downloaded from by 61.160.111.170 on 05/04/14